[1] |
Gisondi P, Fostini AC, Fossà I, et al. Psoriasis and the metabolic syndrome[J]. Clin Dermatol, 2018,36(1):21⁃28. doi: 10.1016/j.clindermatol.2017.09.005.
|
[2] |
Ryan C, Kirby B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities[J]. Dermatol Clin, 2015,33(1):41⁃55. doi: 10.1016/j.det.2014.09.004.
|
[3] |
Poirier S, Mayer G, Poupon V, et al. Dissection of the endogenous cellular pathways of PCSK9⁃induced low density lipoprotein receptor degradation: evidence for an intracellular route[J]. J Biol Chem, 2009,284(42):28856⁃28864. doi: 10.1074/jbc.M109. 037085.
|
[4] |
Fitzgerald K, Frank⁃Kamenetsky M, Shulga⁃Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single⁃blind, placebo⁃controlled, phase 1 trial[J]. Lancet, 2014,383(9911):60⁃68. doi: 10.1016/S0140⁃6736(13)61914⁃5.
|
[5] |
Della BLA, Elshourbagy NA, Mousa SA. Targeting PCSK9 as a promising new mechanism for lowering low⁃density lipoprotein cholesterol[J]. Pharmacol Ther, 2016,164:183⁃194. doi: 10.1016/ j.pharmthera.2016.04.011.
|
[6] |
Tang ZH, Peng J, Ren Z, et al. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF⁃κB pathway[J]. Atherosclerosis, 2017,262:113⁃122. doi: 10.1016/ j.atherosclerosis.2017.04.023.
|
[7] |
Ricci C, Ruscica M, Camera M, et al. PCSK9 induces a pro⁃inflammatory response in macrophages[J]. Sci Rep, 2018,8(1):2267. doi: 10.1038/s41598⁃018⁃20425⁃x.
|
[8] |
Momtazi AA, Banach M, Pirro M, et al. Regulation of PCSK9 by nutraceuticals[J]. Pharmacol Res, 2017,120:157⁃169. doi: 10. 1016/j.phrs.2017.03.023.
|
[9] |
Schulz R, Schlüter KD. PCSK9 targets important for lipid metabolism[J]. Clin Res Cardiol Suppl, 2017,12(Suppl 1):2⁃11. doi: 10.1007/s11789⁃017⁃0085⁃0.
|
[10] |
Liberale L, Montecucco F, Camici GG, et al. Treatment with Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors to reduce cardiovascular inflammation and outcomes[J]. Curr Med Chem, 2017,24(14):1403⁃1416. doi: 10.2174/092986732466 6170303123734.
|
[11] |
Li S, Guo YL, Xu RX, et al. Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease[J]. Atherosclerosis, 2014,234(2):441⁃445. doi: 10.1016/j.atherosclerosis.2014.04.001.
|
[12] |
杜晴, 于晓晶, 李红娟, 等. 类风湿关节炎患者血清前蛋白转化酶枯草溶菌素9水平及其意义[J]. 中华内科杂志, 2017,56(9):655⁃659. doi: 10.3760/cma.j.issn.0578⁃1426.2017.09.007.
|
[13] |
Arican O, Aral M, Sasmaz S, et al. Serum levels of TNF⁃alpha, IFN⁃gamma, IL⁃6, IL⁃8, IL⁃12, IL⁃17, and IL⁃18 in patients with active psoriasis and correlation with disease severity[J]. Mediators Inflamm, 2005,2005(5):273⁃279. doi: 10.1155/MI.2005.273.
|
[14] |
Lynde CW, Poulin Y, Vender R, et al. Interleukin 17A: toward a new understanding of psoriasis pathogenesis[J]. J Am Acad Dermatol, 2014,71(1):141⁃150.
|